1
|
Jones BE, Maerz MD, Bahnson HT, Somasundaram A, McCarthy LH, Speake C, Buckner JH. Fewer LAG-3 + T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2022; 208:594-602. [PMID: 35022272 PMCID: PMC8820445 DOI: 10.4049/jimmunol.2100850] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Accepted: 11/23/2021] [Indexed: 02/03/2023]
Abstract
The coinhibitory receptor lymphocyte activation gene 3 (LAG-3) is an immune checkpoint molecule that negatively regulates T cell activation, proliferation, and homeostasis. Blockade or deletion of LAG-3 in autoimmune-prone backgrounds or induced-disease models has been shown to exacerbate disease. We observed significantly fewer LAG-3+ CD4 and CD8 T cells from subjects with relapsing-remitting multiple sclerosis (RRMS) and type 1 diabetes. Low LAG-3 protein expression was linked to alterations in mRNA expression and not cell surface cleavage. Functional studies inhibiting LAG-3 suggest that in subjects with RRMS, LAG-3 retains its ability to suppress T cell proliferation. However, LAG-3 expression was associated with the expression of markers of apoptosis, indicating a role for low LAG-3 in T cell resistance to cell death. In T cells from subjects with RRMS, we observed a global dysregulation of LAG-3 expression stemming from decreased transcription and persisting after T cell stimulation. These findings further support the potential clinical benefits of a LAG-3 agonist in the treatment of human autoimmunity.
Collapse
Affiliation(s)
- Britta E Jones
- Translational Research Program, Benaroya Research Institute, Seattle, WA
| | - Megan D Maerz
- Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA
| | - Henry T Bahnson
- Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA; and
| | - Ashwin Somasundaram
- Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Lucas H McCarthy
- Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA; and
| | - Cate Speake
- Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA; and
| | - Jane H Buckner
- Translational Research Program, Benaroya Research Institute, Seattle, WA;
| |
Collapse
|
2
|
Böttcher C, Fernández-Zapata C, Schlickeiser S, Kunkel D, Schulz AR, Mei HE, Weidinger C, Gieß RM, Asseyer S, Siegmund B, Paul F, Ruprecht K, Priller J. Multi-parameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass cytometry in patients with early multiple sclerosis. Sci Rep 2019; 9:19471. [PMID: 31857644 PMCID: PMC6923404 DOI: 10.1038/s41598-019-55852-x] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Accepted: 12/03/2019] [Indexed: 12/15/2022] Open
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS). Studies in rodent models demonstrated an association of CNS-infiltrating monocyte-derived macrophages with disease severity. However, little is known about humans. Here, we performed an exploratory analysis of peripheral blood mononuclear cells (PBMCs) isolated from healthy controls and drug-naïve patients with early MS using multiplexed single-cell mass cytometry and algorithm-based data analysis. Two antibody panels comprising a total of 64 antibodies were designed to comprehensively analyse diverse immune cell populations, with particular emphasis on monocytes. PBMC composition and marker expression were overall similar between the groups. However, an increased abundance of CCR7+ and IL-6+ T cells was detected in early MS-PBMCs, whereas NFAT1hiT-bethiCD4+ T cells were decreased. Similarly, we detected changes in the subset composition of the CCR7+ and MIPβhi HLA-DR+ lymphocyte compartment. Only mild alterations were detected in monocytes/myeloid cells of patients with early MS, namely a decreased abundance of CD141hiIRF8hiCXCR3+CD68- dendritic cells. Unlike in Crohn's disease, no significant differences were found in the monocyte fraction of patients with early MS compared to healthy controls. This study provides a valuable resource for future studies designed to characterise and target diverse PBMC subsets in MS.
Collapse
Affiliation(s)
- Chotima Böttcher
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Berlin, Germany.
| | - Camila Fernández-Zapata
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Berlin, Germany
| | - Stephan Schlickeiser
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- BIH Center for Regenerative Therapies (BCRT), Berlin, Germany
| | - Desiree Kunkel
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Berlin Institute of Health, Berlin, 10178, Germany
| | - Axel R Schulz
- German Rheumatism Research Center (DRFZ), Berlin, Germany
| | - Henrik E Mei
- German Rheumatism Research Center (DRFZ), Berlin, Germany
| | - Carl Weidinger
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Division of Gastroenterology, Infectiology and Rheumatology, Medical Department for Gastroenterology, Berlin, Germany
| | - René M Gieß
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Department of Neurology and Clinical and Experimental Multiple Sclerosis Research Center, Berlin, Germany
- NeuroCure Clinical Research Center (NCRC), Berlin, Germany
| | - Susanna Asseyer
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- NeuroCure Clinical Research Center (NCRC), Berlin, Germany
| | - Britta Siegmund
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Division of Gastroenterology, Infectiology and Rheumatology, Medical Department for Gastroenterology, Berlin, Germany
| | - Friedemann Paul
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Department of Neurology and Clinical and Experimental Multiple Sclerosis Research Center, Berlin, Germany
- NeuroCure Clinical Research Center (NCRC), Berlin, Germany
- Berlin Institute of Health, Berlin, 10178, Germany
- Experimental and Clinical Research Center (ECRC), Max Delbrueck Center for Molecular Medicine, Berlin, Germany
| | - Klemens Ruprecht
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- Department of Neurology and Clinical and Experimental Multiple Sclerosis Research Center, Berlin, Germany
| | - Josef Priller
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Berlin, Germany.
- Berlin Institute of Health, Berlin, 10178, Germany.
- DZNE, Berlin Germany, University of Edinburgh and UK Dementia Research Institute, Edinburgh, UK.
| |
Collapse
|
3
|
Boziki M, Lagoudaki R, Melo P, Kanidou F, Bakirtzis C, Nikolaidis I, Grigoriadou E, Afrantou T, Tatsi T, Matsi S, Grigoriadis N. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate. J Neurol Sci 2019; 401:43-50. [DOI: 10.1016/j.jns.2019.03.030] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 02/11/2019] [Accepted: 03/28/2019] [Indexed: 11/29/2022]
|
4
|
Nochevnaya OM, Pereverzeva OV, Sokolova EA, Phillipenko ML, Zamyatina SV, Palaschenko AS, Zhdanova ES, Elchaninova SA, Smagina IV. [The association of the FAS/APO-1 (rs2234767) gene polymorphism with the risk and rapid progression of multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2017; 117:10-13. [PMID: 28617356 DOI: 10.17116/jnevro20171172210-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM To evaluate the association of the FAS/APO-1 (rs2234767) gene polymorphism with the risk of multiple sclerosis and its progression dynamics. MATERIAL AND METHODS A case-control study included 100 patients with recurrent multiple sclerosis (MS), Russians from the Altai Territory, and 100 healthy volunteers. Real-time polymerase chain reaction was used to genotype the 1377G>A polymorphism in the promoter of the FAS/APO-1 (rs2234767) gene. Association of this polymorphism with the risk of multiple sclerosis and its progression was evaluated. RESULTS The G/А genotype and the А-allele were associated with the increased risk of multiple sclerosis. The G/А genotype and the А-allele were associated with the risk of high progression rate of the disease. The G/G genotype and the G-allele had a protective effect. CONCLUSION Predisposition to MS as well as to high progression rate are associated with the FAS/APO-1*G/А gene in Russians living in the Altai Territory. Further research is required to make the conclusion.
Collapse
Affiliation(s)
| | | | - E A Sokolova
- Laboratory of pharmacogenomics Institute of chemical biology and fundamental medicine, Siberian branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - M L Phillipenko
- Laboratory of pharmacogenomics Institute of chemical biology and fundamental medicine, Siberian branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - S V Zamyatina
- Altai State Medical University, Barnaul, Russia, Altai Regional Clinical Hospital, Barnaul, Russia, Laboratory of pharmacogenomics Institute of chemical biology and fundamental medicine, Siberian branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - A S Palaschenko
- Altai State Medical University, Barnaul, Russia, Altai Regional Clinical Hospital, Barnaul, Russia, Laboratory of pharmacogenomics Institute of chemical biology and fundamental medicine, Siberian branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | - E S Zhdanova
- Altai State Medical University, Barnaul, Russia, Altai Regional Clinical Hospital, Barnaul, Russia, Laboratory of pharmacogenomics Institute of chemical biology and fundamental medicine, Siberian branch of the Russian Academy of Sciences, Novosibirsk, Russia
| | | | - I V Smagina
- Altai State Medical University, Barnaul, Russia; Altai Regional Clinical Hospital, Barnaul, Russia
| |
Collapse
|
6
|
Sofo V, Salmeri FM, Di Bella P, Sessa E, D'Aleo G, Trimarchi G, Bramanti P. Short communication: impairment of membrane markers on peripheral blood mononuclear cells and imbalance of cytokine secretion in the pathogenesis of multiple sclerosis active phases. J Interferon Cytokine Res 2006; 25:661-5. [PMID: 16318579 DOI: 10.1089/jir.2005.25.661] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). In active disease, a transmigration of autoreactive T cells to myelin antigens recruited from the peripheral blood (PBMC) to the CNS occurs, and there these cells prolong their survival and contribute to the perpetuation of the inflammation. In the active local lesions of MS patients, these cells display activation and apoptosis surface markers and secrete a range of cytokines. The aim of this research is to study on PBMCs and in the serum of stable and active MS subjects (1) the behavior of the CD40/CD40L system and the consequent balance of Th1 and Th2 cytokines and (2) the apoptosis marker system CD95/CD95L and tumor necrosis factor (TNF)- binding receptors, TNFRI and TNFRII. A possible excess of activation marker expression affecting and driving Th1 cytokine production or a parallel impairment of apoptosis may contribute to MS relapses. Our results may indicate that a dysregulation of early activation and apoptosis receptor systems and a profound and complex imbalance of cytokine production occurred in the peripheral blood of MS patients. This impairment could account for active phases of the disease.
Collapse
Affiliation(s)
- Vincenza Sofo
- Department of Environmental Protection, Section of General Pathology, School of Medicine, University of Messina, Italy.
| | | | | | | | | | | | | |
Collapse
|